Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...

Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...

Shares of the company were down about 3.9% after the bell. The Arizona-based company posted third-quarter revenue of $977.9 million, down 4.9% sequentially, missing estimates of $987.34 million, ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

On Monday, Leerink Partners shifted its stance on Gilead Sciences (NASDAQ:GILD), raising the stock's rating from Market Perform to Outperform. The firm also increased the price target ...